INM has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
INM has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
InMed Pharmaceuticals's yield on cost for the quarter that ended in Dec. 2024 was 0.00.
The historical rank and industry rank for InMed Pharmaceuticals's 5-Year Yield-on-Cost % or its related term are showing as below:
For the Drug Manufacturers - Specialty & Generic subindustry, InMed Pharmaceuticals's 5-Year Yield-on-Cost %, along with its competitors' market caps and 5-Year Yield-on-Cost % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Drug Manufacturers industry and Healthcare sector, InMed Pharmaceuticals's 5-Year Yield-on-Cost % distribution charts can be found below:
* The bar in red indicates where InMed Pharmaceuticals's 5-Year Yield-on-Cost % falls into.
Dividend Yield % and dividend growth of a stock is an important factor for income investors. But if company A raises its dividend constantly faster than company B, company A's future dividend yield might be much higher than Company B's even if their yields are the same now and their stock prices do not change.
Yield on Cost assumes that you buy and the stock today, and hold it for 5 years. If the company raises it dividends at the same rate as it did over the past 5 years, the dividends investors receive annually in 5 years relative to the stock price today.
Therefore, Yield-on-Cost of InMed Pharmaceuticals is calculated as
Yield-on-Cost | = | Dividend Yield % | * | (1 | + | Dividend Growth Rate)^5 |
InMed Pharmaceuticals (NAS:INM) 5-Year Yield-on-Cost % Explanation
Of course the risk here is that the company may not raise its dividends as it did before. The key is to select the companies that can consistently raise its dividends. Usually companies with long history of raising dividends tend to do so.
Thank you for viewing the detailed overview of InMed Pharmaceuticals's 5-Year Yield-on-Cost % provided by GuruFocus.com. Please click on the following links to see related term pages.
Mancini Alexandra Diane Janet | officer: Sr VP, Clinical Reg Affairs | C/O INMED PHARMACEUTICALS INC., SUITE 310 - 815 HASTINGS STREET, VANCOUVER A1 V6C 1B4 |
Andrew Hull | director | C/O INMED PHARMACEUTICALS INC., SUITE 310 - 815 HASTINGS STREET, VANCOUVER A1 V6C 1B4 |
Eric A Adams | director, officer: President & CEO | C/O INMED PHARMACEUTICALS INC., SUITE 310 - 815 HASTINGS STREET, VANCOUVER A1 V6C 1B4 |
Jonathan Tegge | officer: Interim CFO | 217 W. MAIN STREET, SOMERVILLE NJ 08876 |
Sarah Li | officer: VP, Accounting and Controller | 310-815 WEST HASTINGS ST., VANCOUVER Z4 V6C1B4 |
Nicole Lemerond | director | 3 MURRAY HILL ROAD, SCARSDALE NY 10583 |
Bryan T Baldasare | director | 3471 RIVER HILLS DRIVE, CINCINNATI OH 45244 |
Brenda Edwards | officer: Interim CFO | 111-1232 JOHNSON ST., COQUITLAM A1 V3B 4T2 |
Janet P Grove | director | 510 WEST GEORGIA STREET, SUITE 1800, VANCOUVER A1 V5T 4T5 |
Bruce Colwill | officer: CFO | C/O INMED PHARMACEUTICALS INC., SUITE 310 - 815 HASTINGS STREET, VANCOUVER A1 V6C 1B4 |
Shane Aaron Johnson | officer: SVP & GM of BayMedica LLC | 930 TAHOE BLVD., SUITE 802-433, INCLINE VILLAGE NV 89451 |
Adam D. Cutler | director | 9301 AMBERGLEN BOULEVARD, SUITE 100, C/O MOLECULAR TEMPLATES, INC., AUSTIN TX 78729 |
William J Garner | director | 875 MAHLER ROAD, SUITE 235, BURLINGAME CA 94010 |
Catherine Sazdanoff | director | 3471 RIVER HILLS DRIVE, CINCINNATI OH 45244 |
Eric C Hsu | officer: Sr. VP, Pre-Clinical Res/Dev | C/O INMED PHARMACEUTICALS INC., SUITE 310 - 815 HASTINGS STREET, VANCOUVER A1 V6C 1B4 |
From GuruFocus
By GlobeNewswire GlobeNewswire • 02-10-2023
By Stock market mentor Stock market mentor • 01-10-2023
By GuruFocus News • 11-15-2024
By sperokesalga sperokesalga • 02-10-2023
By GuruFocus Research • 03-06-2024
By GuruFocus Research • 03-06-2024
By PurpleRose PurpleRose • 08-09-2022
By GuruFocus News • 01-04-2025
By GuruFocus Research • 03-06-2024
By GuruFocus Research • 03-06-2024
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.